MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

68.58 1.25

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

67.48

Max

69.22

Galvenie mērījumi

By Trading Economics

Ienākumi

-43M

158M

Pārdošana

-126M

1.1B

P/E

Sektora vidējais

336.35

39.564

EPS

1.16

Peļņas marža

15.025

Darbinieki

2,617

EBITDA

-80M

257M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+13.68% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.8B

13B

Iepriekšējā atvēršanas cena

67.33

Iepriekšējā slēgšanas cena

68.58

Ziņu noskaņojums

By Acuity

30%

70%

68 / 376 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. jūl. 15:46 UTC

Galvenie tirgus virzītāji

BitMine Shares Fall After Closing of $250 Million Private Placement

2025. g. 9. jūl. 23:44 UTC

Tirgus saruna

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025. g. 9. jūl. 23:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 9. jūl. 23:42 UTC

Tirgus saruna

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025. g. 9. jūl. 22:59 UTC

Tirgus saruna

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025. g. 9. jūl. 22:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 9. jūl. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 9. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. jūl. 20:26 UTC

Peļņas

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025. g. 9. jūl. 19:18 UTC

Tirgus saruna

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025. g. 9. jūl. 19:03 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025. g. 9. jūl. 18:31 UTC

Tirgus saruna

Some Fed Officials Supported Considering July Cut -- Market Talk

2025. g. 9. jūl. 17:07 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk -2-

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. jūl. 16:14 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 9. jūl. 16:14 UTC

Tirgus saruna

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025. g. 9. jūl. 16:14 UTC

Iegādes, apvienošanās, pārņemšana

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025. g. 9. jūl. 16:12 UTC

Tirgus saruna

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025. g. 9. jūl. 16:08 UTC

Tirgus saruna

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025. g. 9. jūl. 15:31 UTC

Galvenie tirgus virzītāji

BitMine Shares Fall After Closing of $250M Private Placement

2025. g. 9. jūl. 15:31 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025. g. 9. jūl. 15:27 UTC

Tirgus saruna

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025. g. 9. jūl. 14:36 UTC

Iegādes, apvienošanās, pārņemšana

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025. g. 9. jūl. 14:31 UTC

Iegādes, apvienošanās, pārņemšana

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025. g. 9. jūl. 14:26 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 9. jūl. 14:26 UTC

Tirgus saruna

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

13.68% augšup

Prognoze 12 mēnešiem

Vidējais 76.93 USD  13.68%

Augstākais 107 USD

Zemākais 52 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

7

Pirkt

9

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

68 / 376 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation